

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) December 3, 1996

ENZON, INC.

(Exact name of registrant as specified in its charter)

Delaware	0-12957	22-237286
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification)

20 Kingsbridge Road, Piscataway, New Jersey 08854
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (908) 980-4500

(Former name or former address, if changed since last report)

Item 5. Other Events

Enzon, Inc. (the "Enzon" or the "Company") announced at the 1996 Annual Meeting of Shareholders that under Enzon's agreement with the Green Cross Corporation, a Japanese pharmaceutical company, for recombinant Human Serum Albumin, (rHSA) is currently in Phase III clinical trials in Japan as a blood volume expander. The market in Japan for rHSA is approximately \$400 million. While the agreement entitles Enzon to a customary pharmaceutical royalty on product sales, Green Cross has requested reduction of the royalty. Enzon is considering all its options under the agreement.

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 19, 1996

ENZON, INC.
(Registrant)

By: /S/KENNETH J.ZUERBLIS
Kenneth J. Zuerblis
Vice President, Finance
and Chief Financial
Officer